Skip to content

Restrictive or Liberal Oxygen Therapy for Trauma patients

Restrictive vs. Liberal Oxygen Therapy for Trauma patients. PILOT: The TRAUMOX Trial - TRAUMOX trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2017-004480-12-DK
Enrollment
40
Registered
2017-11-17
Start date
2018-01-16
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Victims of trauma are often healthy individuals prior to the incident, but acquire numerous complications including sepsis and pulmonary complications as well as long-term complications and diminished quality of life after the trauma. Understanding the reasons behind these complications and poor outcomes and optimizing care is therefore essential to increase survival rates and quality of life MedDRA version: 20.0 Level: LLT Classification code 10050322 Term: Oxygen supplementation System Organ

Interventions

Trade Name: Oxygen Pharmaceutical Form: Medicinal gas, compressed INN or Proposed INN: OXYGEN Concentration unit: % percent Concentration type: range Concentration number: 0-100

Sponsors

Rigshospitalet
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion Criteria - Age = 18 years, including fertile women* - Blunt/Penetrating trauma patient - Direct transfer from the scene of the accident to Rigshospitalets Traume Center - Trauma team activation * There is no added risk for enrolment of fertile women as oxygen administration is approved for this group of patients. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria: Exclusion Criteria - Patients in cardiac arrest before/at admission - Patients with a suspicion of smoke inhalation - No hospital admission after initial treatment in trauma center

Design outcomes

Primary

MeasureTime frame
Main Objective: The primary objective of this trial is to evaluate whether the maintenance of pragmatic normoxia, avoiding both hyperoxic and hypoxic phases, is feasible within the first 24 hours after trauma, as it may result in a reduction of 30-day mortality and major respiratory complications within 30 days (respiratory failure, pulmonary edema, and pneumonia). We will conduct a pilot study, where 40 patients are randomized to 24 hours of: A. Restrictive, but sufficient oxygen treatment: lowest oxygen delivery that obtains a saturation of = 94% B. Liberal oxygen treatment: 15 L/min oxygen flow initially/ FiO2 =0.8 A. within the low limits of standard of care and does not put patients at risk of receiving worse treatment. B. as close as possible to the standard of care. As no precise guidelines on oxygen delivery for trauma patients within the first 24 hours exist, this will however inevitably vary in practice. ;Secondary Objective: Not applicable;Primary end point(s): Composite Primary Outcomes: 30-day mortality and major respiratory complications within 30 days (pneumonia, acute respiratory distress syndrome (ARDS), acute lung injury (ALI)). ;Timepoint(s) of evaluation of this end point: Any time before hospital discharge (but within 30 days) and after 30 days of trauma

Secondary

MeasureTime frame
Secondary end point(s): Secondary Outcomes • Intensive Care Unit length of stay (ICU LOS) • Hospital length of Stay • Days on ventilator • Within 30 days post trauma (through telephone follow-up if discharged) o Sepsis o Surgical Site Infection (SSI) • 30 days post-trauma (through telephone follow-up if discharged) o Glasgow Outcome Scale Extended (GOSE) ;Timepoint(s) of evaluation of this end point: Any time before hospital discharge (but within 30 days) and after 30 days of trauma

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026